Cognitive and psychomotor effects of three months of escitalopram treatment in elderly patients with major depressive disorder

被引:12
|
作者
Beheydt, Lieve Lia [1 ,2 ]
Schrijvers, Didier [1 ,2 ]
Docx, Lise [1 ,3 ]
Bouckaert, Filip [4 ]
Hulstijn, Wouter [1 ]
Sabbe, Bernard [1 ,2 ]
机构
[1] Univ Antwerp, CAPRI, B-2610 Antwerp, Belgium
[2] Hosp Psychiat, Univ Psychiat Ctr, Duffel, Belgium
[3] Hosp Psychiat, Broeders Alexianen, Boechout, Belgium
[4] Univ Psychiat Ctr KU Leuven, Kortenberg, Belgium
关键词
Major depression; Elderly; Psychomotor retardation; Cognitive; Escitalopram; Functional burden; EXECUTIVE DYSFUNCTION; DOUBLE-BLIND; SYMPTOMS; RETARDATION; PERFORMANCE; OLD;
D O I
10.1016/j.jad.2015.08.041
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Although psychomotor retardation (PR) and cognitive disfunctioning are essential symptoms of elderly depressed patients, the differential effect of treatment with an SSRI in the elderly on these symptoms has hardly got any attention in studies with objective experimental measures. Since effects appear relatively slower in elderly, this study evaluates the effect on cognitive and psychomotor functioning as compared to mood, on four points during a twelve week follow up of monotreatment with escitalopram. Method: 28 non-demented elderly unipolar depressive patients on 5-20 mg escitalopram were compared to 20 matched healthy elderly. All participants underwent a test battery containing clinical depression measures, cognitive measures of processing speed, executive function and memory, clinical ratings of PR, and objective computerized fine motor skill-tests at the start and after 2,6 and 12 weeks. Statistical analysis consisted of a General Linear Model (GLM) repeated measures multivariate analysis of variance of completers to compare the psychomotor and cognitive outcomes of the two groups. Results: Although, apart from the significant mood effect, no interaction effects were found for the psychomotor and cognitive tasks, the means in general show a trend of differential effects in cognitive and psychomotor functions, with smaller effects and delayed timeframes and with presence of subgroups compared to mood effects. Limitation: Longer follow up studies are necessary to evaluate differential long term effects. Conclusion: In elderly, moderate effects of SSRI treatment on mood precede slow or limited effects on cognition and psychomotor retardation. (c) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:47 / 52
页数:6
相关论文
共 50 条
  • [31] Escitalopram is a new and highly efficacious SSRI in the treatment of major depressive disorder
    Montgomery, SA
    Huusom, AKT
    Bothmer, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S254 - S255
  • [32] Superiority of Escitalopram over Paroxetine in the treatment of Major Depressive Disorder (MDD)
    Kasper, S.
    Baldwin, D.
    Boulenger, J. P.
    INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2008, 12 (04) : 337 - 337
  • [33] Escitalopram vs. venlafaxine XR treatment of major depressive disorder
    Montgomery, S
    Bielski, RJ
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2004, 7 : S169 - S169
  • [34] Amelioration of major depressive disorder in epilepsy with escitalopram
    Ravanic, D.
    Jovanovic, M.
    Janjic, V.
    Mihajlovic, G.
    Dejanovic, S. Djukic
    Petrovic, D.
    Ristic, D. Ignjatovic
    Djokovic, D.
    Borovcanin, M.
    Radmanovic, B.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2010, 13 : 160 - 160
  • [35] Comparative efficacy of escitalopram and duloxetine in the acute treatment of major depressive disorder
    Bose, A.
    Gommoll, C.
    Li, D.
    Gandhi, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2007, 17 : S349 - S350
  • [36] Effects of escitalopram therapy on functional brain controllability in major depressive disorder
    Fang, Feng
    Godlewska, Beata
    Cho, Raymond Y.
    Savitz, Sean I.
    Selvaraj, Sudhakar
    Zhang, Yingchun
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 310 : 68 - 74
  • [37] Combining escitalopram with gaboxadol provides no additional benefit in the treatment of patients with severe major depressive disorder
    Kasper, S.
    Ebert, B.
    Larsen, K.
    Tonnoir, B.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2011, 21 : S408 - S408
  • [38] Spotlight on escitalopram in the management of major depressive disorder
    Murdoch, D
    Keam, SJ
    CNS DRUGS, 2006, 20 (02) : 167 - 170
  • [39] Effective dose of escitalopram major depressive disorder
    Bech, P
    Andersen, HF
    NORDIC JOURNAL OF PSYCHIATRY, 2005, 59 (05) : 406 - 407
  • [40] Spotlight on Escitalopram in the Management of Major Depressive Disorder
    David Murdoch
    Susan J. Keam
    CNS Drugs, 2006, 20 : 167 - 170